BeOne Medicines (NASDAQ:ONC – Get Free Report) and Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.
Profitability
This table compares BeOne Medicines and Eyepoint Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 10.70% | 14.23% | 7.82% |
| Eyepoint Pharmaceuticals | -10,994.73% | -135.81% | -108.35% |
Earnings and Valuation
This table compares BeOne Medicines and Eyepoint Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeOne Medicines | $5.34 billion | 7.28 | $286.93 million | $5.68 | 62.41 |
| Eyepoint Pharmaceuticals | $31.37 million | 9.34 | -$231.96 million | ($3.74) | -0.91 |
BeOne Medicines has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
BeOne Medicines has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for BeOne Medicines and Eyepoint Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 0 | 2 | 13 | 2 | 3.00 |
| Eyepoint Pharmaceuticals | 1 | 6 | 4 | 0 | 2.27 |
BeOne Medicines currently has a consensus price target of $404.93, indicating a potential upside of 14.23%. Eyepoint Pharmaceuticals has a consensus price target of $25.70, indicating a potential upside of 655.88%. Given Eyepoint Pharmaceuticals’ higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than BeOne Medicines.
Insider & Institutional Ownership
48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
BeOne Medicines beats Eyepoint Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
